A higher frequency of PTEN loss is observed in more aggressive stages of the disease including castration-resistant prostate cancers (CRPC) and metastatic disease, with PTEN lost in 40–60% of these cases [2,3,4,5,6]. Here, PTEN is linked to metastatic neoplasm.